Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.46 |
| ▸ | F2 | P00734 | 4/20 | 0.46 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | KLK1 | P06870 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | GPR39 | O43194 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122136 | 0.92 | NPC1 (0.57) | ESR1MEN1NPC1KMT2AHIF1A | |
| SCHEMBL5122443 | 0.86 | ESR1 (0.49) | ESR1PDE5ATGFBR1 | |
| SCHEMBL5129136 | 0.86 | ESR1 (0.49) | ESR1MEN1NPC1KMT2AHIF1A | |
| SCHEMBL23598961 | 0.85 | LMNA (0.58) | ESR1MEN1NPC1KMT2AHIF1A | |
| SCHEMBL31336893 | 0.85 | LMNA (0.58) | ESR1MEN1NPC1KMT2AHIF1A | |
| SCHEMBL5129883 | 0.84 | KDM4E (0.52) | ESR1MEN1NPC1KMT2AHIF1A | |
| SCHEMBL5122734 | 0.83 | MEN1 (0.48) | MEN1NPC1KMT2AHIF1APDE5A | |
| SCHEMBL5119670 | 0.83 | HIF1A (0.46) | ESR1MEN1KMT2AHIF1APDE5A | |
| SCHEMBL5123277 | 0.83 | HIF1A (0.46) | ESR1MEN1NPC1KMT2AHIF1A | |
| SCHEMBL5129882 | 0.82 | ESR1 (0.54) | ESR1MEN1KMT2APDE5ATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6133271-A | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | ESR1 2256/4885MEN1 696/4885NPC1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.